

# Preliminary Antiviral Efficacy and Safety of Repeat Dosing of Imdusiran (AB-729) Followed by VTP-300 With or Without Nivolumab in Virally-Suppressed, Non-Cirrhotic Subjects With Chronic Hepatitis B (CHB)

Grace Lai Hung Wong,<sup>1</sup> Man-Fung Yuen,<sup>2</sup> Patrick Kennedy,<sup>3</sup> Ashley Brown,<sup>4</sup> Chi-Yi Chen,<sup>5</sup> Gin-Ho Lo,<sup>6</sup> Pei-Yuan Su,<sup>7</sup> Sheng-Shun Yang,<sup>8</sup> Kosh Agarwal,<sup>9</sup> Deana Antonello,<sup>10</sup> Elina Medvedeva,<sup>10</sup> Emily P. Thi,<sup>10</sup> Christine Espirito,<sup>10</sup> Christina Iott,<sup>10</sup> Ingrid Graves,<sup>10</sup> Sharie C. Ganchua,<sup>10</sup> Sanjana Kangabam,<sup>10</sup> Timothy Eley,<sup>10</sup> Tom Evans,<sup>11</sup> Bethan Jones,<sup>11</sup> Leon Hooftman,<sup>11</sup> Mark Anderson,<sup>12</sup> Tiffany Fortney,<sup>12</sup> Gavin Cloherty,<sup>12</sup> Gaston Picchio,<sup>10</sup> Karen Sims,<sup>10</sup> Tilly Varughese<sup>10</sup>


<sup>1</sup>The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; <sup>2</sup>The University of Hong Kong, Queen Mary Hospital, Hong Kong, China; <sup>3</sup>Liver Centre, Bizard Institute, Barts and The London SMD, London, UK; <sup>4</sup>Imperial College Healthcare NHS Trust, London, UK; <sup>5</sup>Chia-Yi Christian Hospital, Chia-Yi City, Taiwan; <sup>6</sup>E-Da Hospital, Kaohsiung, Taiwan; <sup>7</sup>Changhua Christian Hospital, Changhua, Taiwan; <sup>8</sup>Taichung Veterans General Hospital, Taichung, Taiwan; <sup>9</sup>King's College Hospital, London, UK; <sup>10</sup>Arbutus Biopharma, Warminster, PA, USA; <sup>11</sup>Barinthus Biotherapeutics, Harwell, UK; <sup>12</sup>Abbott Laboratories, Abbott Diagnostics, Infectious Disease Research, Abbott Park, IL, USA

## BACKGROUND

- Current approved therapies for chronic hepatitis B (CHB) slow or prevent the development of hepatitis B virus (HBV)-related liver complications but do not typically lead to functional cure (FC)<sup>1-4</sup>
- Suppression of hepatitis B surface antigen (HBsAg) and other viral antigen production and induction of HBV-specific T-cell responses are likely required to achieve FC<sup>1</sup>
- Imdusiran (IDR; AB-729) is a subcutaneously administered N-acetylgalactosamine-conjugated, single trigger, pan-genotypic small interfering RNA therapeutic that blocks all HBV RNA transcripts, including HBV X protein, resulting in suppression of viral replication and production of all viral antigens<sup>5</sup>
- VTP-300 is Barinthus Biotherapeutics' investigational HBV immunotherapeutic with 2 components: a chimpanzee adenoviral vector (ChAdOx1-HBV) and a modified vaccinia Ankara (MVA-HBV), both encoding the inactivated polymerase, core, and the entire surface antigen from a consensus genotype C HBV<sup>6</sup>
- Single and multiple doses of low-dose nivolumab (LDN; 0.3 mg/kg) are being examined to potentiate reduction of HBsAg and are well tolerated with a low risk of immune-mediated events in several CHB clinical trials, including Barinthus Biotherapeutics' HBV003 trial (NCT05343481)<sup>7,8</sup>
- IM-PROVE II (AB-729-202; ACTRN12622000317796) is an ongoing phase 2a study assessing the safety, pharmacodynamics, and immunogenicity of repeat doses of IDR followed by VTP-300 (Group A), placebo (Group B), or VTP-300 ± LDN (Group C) in nucleos(t)ide analogue (NA)-suppressed CHB subjects<sup>9</sup>
- Data for 20/22 subjects who reached Week 48/end of treatment (EOT) from Group C are reported here

## MATERIALS AND METHODS

### IM-PROVE II (AB-729-202) Group C Study Design



- Group C was added as an amendment to the study based on data from the HBV002 (NCT04778904) and HBV003 studies that showed addition of LDN to VTP-300 increased both the number of subjects responding and the magnitude of HBsAg decline<sup>7,8,10</sup>
- After the initiation of Group C, the protocol was further amended to exclude subjects at risk of immune-related thyroiditis (family/current history of thyroid disease, presence of thyroid auto-antibodies, or abnormal thyroid function tests) from receiving LDN following reports of mild/moderate thyroid dysfunction in some subjects in the HBV003 trial<sup>7</sup> (eligible to receive LDN, n=13; not eligible, n=9)

### Table 1. Study Assay Methods

| Parameter                          | Assay method  | Assay cutoff                                  |
|------------------------------------|---|---|
| ALT                                | —   | ULN = 44 U/L for males and 41 U/L for females |
| Immune biomarkers                  | Luminex® Assays (MilliporeSigma)                            | —   |
| HBsAg (quantitative)               | Liaison® XL assay (Diasorin)                                | LLOQ = 0.05 IU/mL                             |
| Ultrasensitive HBsAg (qualitative) | ARCHITECT HBsAg Next Qualitative Assay (Abbott Diagnostics) | LLOD = 0.005 IU/mL                            |
| Anti-HBs                           | ADVIA Centaur Anti-HBs2 (Siemens)                           | LLOQ = 10 IU/L                                |

ALT, alanine aminotransferase; anti-HBs, anti-hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; LLOD, lower limit of detection; LLOQ, lower limit of quantitation; ULN, upper limit of normal.

## RESULTS

Table 2. Demographics and Baseline Characteristics

| Parameter                    | Group A IDR + VTP-300 N=20 | Group B IDR + Placebo N=20 | Group C IDR + VTP-300 + LDN N=13 | Group C IDR + VTP-300 N=9 | Total N=62  |
|------------------------------|----------------------------|----------------------------|----------------------------------|---------------------------|-------------|
| Age, mean (SD), y            | 52.2 (6.5)                 | 44.3 (8.3)                 | 40.6 (8.2)                       | 47.2 (9.2)                | 46.5 (8.9)  |
| Males, n (%)                 | 14 (70)                    | 14 (70)                    | 9 (69)                           | 6 (67)                    | 43 (69)     |
| Race, n (%)                  |                            |                            |                                  |                           |             |
| Asian                        | 18 (90)                    | 19 (95)                    | 12 (92)                          | 8 (89)                    | 57 (92)     |
| Black/African American       | 1 (5)                      | 1 (8)                      | 1 (8)                            | 1 (11)                    | 3 (5)       |
| White                        | 1 (5)                      | 1 (5)                      | 0                                | 0                         | 2 (3)       |
| Genotype, n (%) <sup>a</sup> |                            |                            |                                  |                           |             |
| A                            | 0                          | 0                          | 0                                | 1 (11)                    | 1 (2)       |
| B                            | 5 (25)                     | 7 (35)                     | 8 (62)                           | 4 (44)                    | 24 (39)     |
| C                            | 7 (35)                     | 7 (35)                     | 3 (23)                           | 4 (44)                    | 21 (34)     |
| D                            | 1 (5)                      | 0                          | 0                                | 0                         | 1 (2)       |
| HBeAg positive, n (%)        | 4 (20)                     | 10 (50)                    | 3 (23)                           | 1 (11)                    | 18 (29)     |
| HBsAg, IU/mL                 |                            |                            |                                  |                           |             |
| Mean (SD)                    | 1123 (1078)                | 1135 (998)                 | 1105 (1093)                      | 1296 (1468)               | 1148 (1092) |
| <1000 IU/mL, n (%)           | 11 (55)                    | 10 (50)                    | 8 (62)                           | 6 (67)                    | 35 (56)     |
| Range                        | 95-4000                    | 100-3300                   | 93-3200                          | 270-4000                  | 93-4000     |
| ALT, mean (SD), U/L          | 20.7 (9.5)                 | 22.1 (11.1)                | 26.9 (9.5)                       | 25.2 (14.9)               | 23.1 (10.9) |

ALT, alanine aminotransferase; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; IDR, imdusiran; LDN, low-dose nivolumab. <sup>a</sup>Genotype could not be determined in 15 subjects (Group A, n=7; Group B, n=5; Group C VTP-300 + LDN, n=2).

- Demographics, such as sex and race, and baseline mean HBsAg and ALT values were similar across all groups in the study

Table 3. Treatment Administration and NA Discontinuation Summary in Group C

| n/N (%)                                   | Group C IDR + VTP-300 + LDN N=13 | Group C IDR + VTP-300 N=9 | Total N=22  |
|---|----------------------------------|---------------------------|-------------|
| <b>Treatment administration</b>           |                                  |                           |             |
| Week 30: MVA-HBV ± LDN                    | 13/13 (100)                      | 9/9 (100)                 | 22/22 (100) |
| Week 38: MVA-HBV boost ± LDN <sup>a</sup> | 5/13 (38)                        | 4/9 (44)                  | 9/22 (41)   |
| <b>NA discontinuation</b>                 |                                  |                           |             |
| Reached Week 48/EOT                       | 13/13 (100)                      | 7/9 (78)                  | 20/22 (91)  |
| Discontinued NA therapy                   | 9/13 (69)                        | 5/7 (71)                  | 14/20 (70)  |
| Did not meet NA stopping criteria         | 4/13 (31)                        | 2/7 (29)                  | 6/20 (30)   |
| HBeAg positive                            | 3/4 (75)                         | 0/2 (0)                   | 3/6 (50)    |
| HBsAg >100 IU/mL                          | 0/4 (0)                          | 2/2 (100)                 | 2/6 (33)    |
| HBV DNA >LLOQ                             | 1/4 (25)                         | 0/2 (0)                   | 1/6 (17)    |

EOT, end of treatment; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IDR, imdusiran; LDN, low-dose nivolumab; LLOQ, lower limit of quantitation; NA, nucleos(t)ide analogue. <sup>a</sup>Received if HBsAg ≤10 IU/mL at Week 34.


Table 4. Mean HBsAg Change From Baseline and Key Milestones in Group C

| Study week  | Mean (SE) change from baseline, log <sub>10</sub> IU/mL (SE) [n] |                  | HBsAg <100 IU/mL, n/N (%) | HBsAg <10 IU/mL, n/N (%) | HBsAg <LLOQ, n/N (%) |
|-------------|--|------------------|---------------------------|--------------------------|----------------------|
|             | VTP-300 + LDN  | VTP-300          |                           |                          |                      |
| Baseline    | 2.83 (0.11) [22]   | 2/22 (9)         | 0/22 (0)                  | 0/22 (0)                 | 0/22 (0)             |
| Week 12     | -1.33 (0.12) [22]  | 15/22 (68)       | 7/22 (32)                 | 0/22 (0)                 | 0/22 (0)             |
| Week 26     | -1.97 (0.11) [22]  | 21/22 (96)       | 12/22 (55)                | 0/22 (0)                 | 0/22 (0)             |
|             | VTP-300 + LDN  | VTP-300          | VTP-300 + LDN             | VTP-300                  | VTP-300 + LDN        |
| Week 34     | -2.28 (0.20) [13]  | -1.94 (0.17) [9] | 12/13 (92)                | 8/9 (89)                 | 7/13 (54)            |
| Week 48/EOT | -2.36 (0.30) [13]  | -1.70 (0.31) [7] | 12/13 (92)                | 5/7 (71)                 | 3/13 (23)            |

EOT, end of treatment; HBsAg, hepatitis B surface antigen; IDR, imdusiran; LDN, low-dose nivolumab; LLOQ, lower limit of quantitation; Q8W, every 8 weeks.


- After 4 doses of IDR, 96% (21/22) of subjects achieved HBsAg <100 IU/mL at the time of initial VTP-300 administration at Week 26
- Subjects in Group C who received IDR + VTP-300 + LDN were more likely to reach HBsAg values <100 and <10 IU/mL, and 23% (3/13) reached below the lower limit of quantitation (LLOQ) at Week 48/EOT

Figure 1. Mean HBsAg Change From Baseline by Treatment Group




- Subjects in Group C receiving IDR + VTP-300 + LDN (n=13) had a significantly greater mean HBsAg log<sub>10</sub> decline at Week 48 compared with all other groups (-0.73 [95% CI: -1.33, -0.14]; P=0.017)

Figure 2. Individual Subject HBsAg Declines by Treatment Group in Group C



- By Week 48, 3 subjects in Group C IDR + VTP-300 + LDN reached HBsAg <LLOQ
- Baseline HBsAg values of the 3 subjects were 480, 98, and 150 IU/mL, which decreased to 2.8, 2.6, and 0.2 IU/mL, respectively, at the initial VTP-300 dose at Week 26
- All 3 subjects had samples tested by the ultrasensitive Abbott HBsAg Next Qualitative Assay and 1 of the 3 subjects was negative (non-reactive) for HBsAg at Weeks 42 and 48
  - The subject had HBsAg values at baseline and Week 26 of 98.0 and 2.6 IU/mL, respectively
- To date, an additional dose of MVA-HBV ± LDN does not appear to result in further significant HBsAg decline at Week 48 in most subjects, but additional follow-up will evaluate its effect at later time points

Figure 3. Immune Biomarker Evaluation in Subjects With HBsAg Loss in Group C



AIT, U/L

HBsAg, log<sub>10</sub> IU/mL

Time, weeks

HBsAg, log<sub>10</sub> IU/mL

Time, weeks

HBsAg, log<sub>10</sub> IU/mL

Time, weeks

HBsAg, log<sub>10</sub> IU/mL

Time, weeks

● HBsAg ● sPD-1 ● sLAG-3 ● sPD-L1 ● IFN-γ ● ALT

BTIA, B- and T-lymphocyte attenuator; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; GITR, glucocorticoid-induced tumor necrosis factor-related protein; GITRL, glucocorticoid-induced tumor necrosis factor receptor-related protein ligand; GROα, growth-regulated protein alpha; ICOS, inducible T cell costimulator; IFNγ, interferon gamma; PDGF, platelet-derived growth factor; sLAG-3, soluble lymphocyte activation gene 3; sPD-L1, soluble programmed death ligand-1; sPD-1, soluble programmed death protein 1; TLR-2, toll-like receptor 2; VEGF, vascular endothelial growth factor.

<sup>a</sup>Elevations in soluble GROα, PDGF-AA, VEGF, BTIA, CD28, GITR, GITRL, TLR-2, CTLA-4, CD80, CD86, and ICOS also present in Subject 22. Subject 22's immune biomarker profile is similar to those observed in IM-PROVE I subjects (see Poster #425).<sup>11</sup>

- Increases in soluble immune biomarkers associated with immune checkpoint proteins, inflammation, and T-cell activation were observed in subjects in Group C who had HBsAg <LLOQ at any point through Week 48 (Subjects 36, 37, and 22)
- No marked production of anti-hepatitis B surface antibodies was seen in these subjects through Week 48
- No immune biomarker increases were observed for Subject 29, who had similar HBsAg baseline levels as Subjects 36, 37, and 22 but did not achieve HBsAg loss through Week 48

Table 5. On-Treatment Safety in Group C

| Subjects, n (%) [events]  | Group C IDR + VTP-300 + LDN N=13 | Group C IDR + VTP-300 N=9 |
|---------------------------|----------------------------------|---------------------------|
| Any TEAE <sup>a</sup>     | 6 (46) [22]                      | 6 (67) [11]               |
| Grade 1                   | 4 (31) [19]                      | 5 (56) [10]               |
| Grade 2                   | 2 (15) [3]                       | 1 (11) [1]                |
| Grade 3 or 4              | 0                                | 0                         |
| Study drug-related TEAEs  |                                  |                           |
| IDR                       | 0                                | 0                         |
| VTP-300 <sup>b</sup>      | 3 (23) [12]                      | 0                         |
| LDN <sup>c</sup>          | 2 (15) [9]                       | 0                         |
| SAEs                      | 0                                | 0                         |
| Treatment discontinuation | 0                                | 0                         |

IDR, imdusiran; LDN, low-dose nivolumab; SAE, serious adverse event; TEAE, treatment-emergent adverse event. <sup>a</sup>No individual TEAEs occurred in ≥2 subjects per treatment group. <sup>b</sup>Most TEAEs related to VTP-300 and LDN were Grade 1 and post-procedural; these included injection site pain, injection pruritus, fever, headache, rhinorrhea, and pruritus.

- In Group C, IDR, VTP-300, and LDN were all well tolerated, with no Grade 3 or 4 treatment-emergent adverse events (TEAEs), no treatment discontinuations, and few study drug-related TEAEs
- There were no Grade 3 or 4 laboratory abnormalities in Group C or any laboratory abnormalities deemed related to any study drugs
- In the 13 subjects who received LDN in Group C, no significant thyroid-stimulating hormone or free thyroxine abnormalities were detected, and no thyroid-related symptoms were reported

## CONCLUSIONS

- IDR treatment for 24 weeks (4 doses) led to a mean decline from baseline in HBsAg of -1.97 log<sub>10</sub> IU/mL by Week 26, consistent with data from Groups A and B<sup>9</sup>
- At Week 48, greater mean log<sub>10</sub> declines in HBsAg levels were seen in the group that received IDR + VTP-300 + LDN, which was statistically significant compared with the other groups
- 3 subjects receiving IDR + VTP-300 + LDN had HBsAg values <LLOQ at Week 48, which was not observed in the other treatment groups
- The IDR + VTP-300 + LDN regimen was well tolerated and did not result in any thyroid-related TEAEs
- These early data for the IDR + VTP-300 + LDN combination in virally suppressed CHB subjects is promising; further follow-up is ongoing and will provide insight on the possibility of functional cure with this regimen

## ACKNOWLEDGEMENTS

Arbutus Biopharma and Barinthus Biotherapeutics thank all participating subjects and their families; the investigators and site staff; Novotech CRO; Eurofins; Maksym Chernyakhovskyy (Arbutus) and Crystal Grant (Arbutus) for data management assistance; Deepa Patel (Arbutus), Dereck Tait (Barinthus), Louise Bussey (Barinthus), Henrik Sorenson (Barinthus), and Vicky Wheeler (Barinthus) for study support; and the imdusiran (AB-729) and VTP-300 Research and Development Teams. The IM-PROVE II study was sponsored by Arbutus Biopharma and Barinthus Biotherapeutics. Editorial assistance and graphic design support for this poster were provided under the direction of the authors by MedThink SciCom and funded by Arbutus Biopharma.

## REFERENCES

<sup>1</sup>EASL. *J Hepatol*. 2017;67:370-398. <sup>2</sup>Sarin et al. *Hepatol Int*. 2016;10:1-98. <sup>3</sup>Terrault et al. *Hepatology*. 2018;67:1560-1599. <sup>4</sup>Ghany et al. *Hepatology*. 2023;78:1654-1673. <sup>5</sup>Thi et al. *ACS Infect Dis*. 2024;10:3640-3649. <sup>6</sup>Evans et al. *J Hepatol*. 2023;78:S1169-S1170. <sup>7</sup>Yuen et al. *EASL 2024*; Milan, Italy. Poster WED-375. <sup>8</sup>Gane et al. *J Hepatol*. 2019;71:900-907. <sup>9</sup>Agarwal et al. *EASL 2024*; Milan, Italy. Oral presentation 505. <sup>10</sup>Evans et al. *EASL 2023*; Vienna, Austria. Poster SAT-198. <sup>11</sup>Thi et al. *AASLD 2024*; San Diego, CA. Poster 425.

## CONTACT INFORMATION AND DISCLOSURES

Corresponding Author: Tilly Varughese, MD  
Medical Director, Clinical Development  
Arbutus Biopharma Inc., 701 Veterans Circle, Warminster, PA 18974  
Email: [tvarughese@arbutusbio.com](mailto:tvarughese@arbutusbio.com)

Grace Lai Hung Wong has received grants or contracts from Gilead Sciences; consulting fees from AstraZeneca, Gilead Sciences, GSK, and Janssen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbott, AbbVie, Ascleris, Bristol-Myers Squibb, Echosens, Gilead Sciences, GSK, Janssen, and Roche; and support for attending meetings from Gilead Sciences. Authors affiliated with Arbutus Biopharma are employees and may own company stock.

[www.arbutusbio.com](http://www.arbutusbio.com)